| Literature DB >> 25380603 |
Roberta La Piana1, Michel Vanasse2, Bernard Brais3, Genevieve Bernard4.
Abstract
Allan-Herndon-Dudley syndrome is an X-linked disease caused by mutations in the solute carrier family 16 member 2 (SLC16A2) gene. As SLC16A2 encodes the monocarboxylate transporter 8 (MCT8), a thyroid hormone transporter, patients with Allan-Herndon-Dudley syndrome present a specific altered thyroid hormone profile. Allan-Herndon-Dudley syndrome has been associated with myelination delay on the brain magnetic resonance imaging (MRI) of affected subjects. We report a patient with Allan-Herndon-Dudley syndrome characterized by developmental delay, hypotonia, and delayed myelination caused by a novel SLC16A2 mutation (p.L291R). The thyroid hormones profile in our patient was atypical for Allan-Herndon-Dudley syndrome. The follow-up examinations showed that the progression of the myelination was not accompanied by a clinical improvement. Our paper suggests that SLC16A2 mutations should be investigated in patients with myelination delay even when the thyroid function is not conclusively altered.Entities:
Keywords: Allan-Herndon-Dudley syndrome; SLC16A2; myelination delay; thyroid function
Mesh:
Substances:
Year: 2014 PMID: 25380603 DOI: 10.1177/0883073814555189
Source DB: PubMed Journal: J Child Neurol ISSN: 0883-0738 Impact factor: 1.987